IRIS - Res&Arch Institutional Research Information System - Research & Archive

MENCARELLI, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.178
EU - Europa 1.688
AS - Asia 419
Continente sconosciuto - Info sul continente non disponibili 5
SA - Sud America 4
AF - Africa 1
Totale 4.295
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.168
UA - Ucraina 412
IE - Irlanda 400
SE - Svezia 214
IT - Italia 210
VN - Vietnam 144
HK - Hong Kong 120
DE - Germania 116
FI - Finlandia 112
RU - Federazione Russa 82
CN - Cina 71
FR - Francia 49
TR - Turchia 47
GB - Regno Unito 26
RO - Romania 19
CH - Svizzera 18
SG - Singapore 16
KR - Corea 12
CA - Canada 9
BE - Belgio 7
CZ - Repubblica Ceca 6
EU - Europa 5
GR - Grecia 5
LB - Libano 4
PL - Polonia 4
UZ - Uzbekistan 4
NL - Olanda 3
AT - Austria 2
BR - Brasile 2
AE - Emirati Arabi Uniti 1
CL - Cile 1
CO - Colombia 1
DK - Danimarca 1
DZ - Algeria 1
HU - Ungheria 1
LT - Lituania 1
MX - Messico 1
Totale 4.295
Salva come PNG Salva come JPEG
Città #
Chandler 481
Dublin 400
San Mateo 224
Jacksonville 190
Wilmington 149
Dong Ket 144
Hong Kong 120
Altamura 119
Medford 100
Princeton 100
Lawrence 83
Andover 69
Ann Arbor 66
Perugia 58
Beijing 47
Izmir 46
Des Moines 42
Ashburn 40
Falls Church 35
Saint Petersburg 28
Boardman 27
Norwalk 17
Helsinki 14
New York 14
San Paolo di Civitate 14
Timisoara 13
Los Angeles 11
Woodbridge 11
Singapore 10
Ottawa 8
Brussels 7
Bucharest 6
Dearborn 6
Auburn Hills 5
Houston 5
Moscow 5
Redwood City 4
Shanghai 4
Den Haag 3
Lausanne 3
Phoenix 3
Rovato 3
Frankfurt Am Main 2
Redmond 2
Simi Valley 2
São Paulo 2
Al Ain City 1
Alameda 1
Atatürk 1
Atlanta 1
Budapest 1
Cartagena 1
Centro 1
Copenhagen 1
Deruta 1
Edinburgh 1
Falkenstein 1
Hanover 1
Kiev 1
Ludwigshafen 1
Miami 1
Moline 1
Montreal 1
Nanjing 1
Pasadena 1
Pensacola 1
Philadelphia 1
Prague 1
Rome 1
Salerno 1
San Diego 1
San Jose 1
Seattle 1
Seoul 1
Tappahannock 1
Vienna 1
Šiauliai 1
Totale 2.773
Salva come PNG Salva come JPEG
Nome #
Recombinant galectin-1 prevents experimental colitis in mice via T cell apoptosis. 155
GITR modulates innate and adaptive mucosal immunity during the development of experimental colitis in mice 89
An NO-derivative of acetaminophen, NCX-701, spares the liver by inhibiting Fas-dependent apoptosis 88
Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. 85
Activation of the farnesoid-X receptor protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs in mice. 81
Activation of the bile acid receptor GPBAR1 protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs and aspirin in mice. 81
A nitro-arginine derivative of trimebutine (NO2-Arg-Trim) attenuates pain induced by colorectal distension in conscious rats. 66
Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. 66
Antiatherosclerotic effect of farnesoid X receptor. 66
Reciprocal regulation of the bile acid-activated receptor FXR and the interferon-gamma-STAT-1 pathway in macrophages. 65
Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition 65
5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. 61
Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation. 60
NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension 60
Activation of FXR Improves Myocardial Fatty Acid Metabolism in a Rodent Model of Liver Steatosis 59
An essential role of Farnesoid X-Receptor in regulating intestinal fibrosis in murine model of chronic colitis 59
Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. 57
a Farnesoid-X-Receptor (FXR)-Glucocorticoid Receptor (GR) Cascade Regulates Intestinal Innate Immunity in Response to FXR Activation 57
Dissociation of intestinal and hepatic activities of FXR and LXRα supports metabolic effects of terminal ileum interposition in rodents. 57
A beta-oxidation-resistant lipoxin A(4) analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction 55
Nitric oxide protects againist HIV gp 120 endothelial injury. 52
Proteinase activated receptor (PAR)-2 agonistic peptide protects from Th-1 mediated liver injury in mice. 52
Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation 51
FXR mediates a chromatin looping in the GR promoter thus promoting the resolution of colitis in rodents. 51
Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice. 50
The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice. 50
Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug leflunomide in a PPAR-γ-dependent manner. 50
Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA 50
NCX-1000, an NO derivative of UDCA, releases NO and protects against portal hypertension by inhibiting hepatic stellate cell contraction. 50
3-oxa-lipoxin A4 analog treats colitis induced by Dss by attenuating inflammation and immunity. 50
The HIV Matrix Protein p17 subverts Nuclear Receptors Expression and induces a STAT1-Dependent Proinflammatory Phenotype in Monocytes 49
Proteinase activated receptor (PAR)-2 protects against colitis in mice. Evidence for direct modulation of lamina propria T lymphocytes. 49
The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease. 48
Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. 48
Farnesoid X receptor suppresses constitutive androstane receptoractivity at the multidrug resistance protein-4 promoter. 48
Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. 48
Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatorybowel diseases and arthritis 48
An NO derivative of ursodeoxycholic acid protects against Fas-mediated liver injury by inhibiting caspase activity 48
Role of the FXR in Regulating Bile Acid Homeostasis and Relevance for Human Diseases 47
IL-1 beta converting enzyme is a target for nitric oxide-releasing aspirin: new insights in the antiinflammatory mechanism of nitric oxide-releasing nonsteroidal antiinflammatory drugs. 47
Counter-regulatory role of bile acid activated receptors in immunity andinflammation. 47
The third gas: H2S regulates perfusion pressure in both theisolated and perfused normal rat liver and in cirrhosis. 47
Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis. 47
4-Methylenesterols from Theonella swinhoei sponge are natural pregnane-X-receptor agonists and farnesoid-X-receptor antagonists that modulate innate immunity. 46
Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. 45
COX-2 selective inhibitors cause gastric damage in aspirin treated rats. Protective effect of nitroaspirin (NCX-4016). 45
Mechanisms to prevent the toxicity of chronic neuroinflammation on forebrain cholinergic neurons 45
Critical role of toll-like receptors in modulating GM-CSF activity in rodent models of colitis 45
A hydrogen-sulfide releasing derivative of mesalamine exhibits markedly enhanced anti-inflammatory effects in experimental colitis 44
Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NO-pegylated epirubicin. 43
Inhibition of NF-κB by a PXR-dependent pathwaymediates counter-regulatory activities of rifaximin on innate immunity inintestinal epithelial cells. 43
The nuclear receptor FXR regulates hepatic transport and metabolism of glutamine and glutamate 42
The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. 41
Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment. 41
VLA-1 immunoneutralization protects against colon damage in a mouse model of colitis 41
The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. 41
SHP-dependent and -independent induction of peroxisomeproliferator-activated receptor-γ by the bile acid sensor farnesoid X receptorcounter-regulates the pro-inflammatory phenotype of liver myofibroblasts. 39
FXR an emerging therapeutic target for the treatment of atherosclerosis. 39
The bile acid receptor FXR is a modulator of intestinal innate immunity. 39
Gene Expression Changes Induced by HIPEC in a Murine Model of Gastric Cancer 39
Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. 38
The methionine connection: homocysteine and hydrogen sulfide exert opposite effects on hepatic microcirculation in rats. 38
Farnesoid-X-receptor (FXR) ligands induce a small heterodimer partner (SHP)-dependent upregulation of PPAR-gamma in hepatic stellate cells and in rat model of liver fibrosis. 38
FXR Activation Reverses Insulin Resistance and Protects Against NASH Development 38
CCR5 Antagonism by Maraviroc Reduces the Potential for Gastric Cancer Cell Dissemination. 38
Epigenetic modulation by methionine deficiency attenuates the potential for gastric cancer cell dissemination. 37
Inhibition of hydrogen sulfide generation contributes to gastric injury caused byanti-inflammatory nonsteroidal drugs. 36
Instruction of Intestinal Microbiota by VSL#3 Reverses NASH and Accelerated Atherosclerosis Caused by Intestinal Inflammation in ApoE(-/-) Mice 35
In vivo administration of ritonavir worsens intestinal damage caused by cyclooxygease inhibitors. 35
Hydrogen sulphide induces micro opioid receptor-dependent analgesia in a rodent model of visceral pain. 34
Different sensitivity of lamina propria T-cell subsets to nitric oxide-induced apoptosis explains immunomodulatory activity of a nitric oxidereleasing derivative of mesalamine in rodent colitis. 34
The nuclear receptor SHP (small heterodimer partner) mediates inhibitory effects of farnesoid-X-receptor (FXR) on hepatic stellate cells and protects against liver fibrosis in rodents. 34
NCX-999, a NO-releasing derivative of UDCA, modulates hepatic stellate cells and reduces vasomotor response to nor-epinefrine in intact rats 34
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity. 31
Co-administration of nitric oxide-aspirin (NCX-4016) andaspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans. 31
Protective effects of granulocyte macrophage colony stimulating factor (gm-Csf) in Hapten-induced colitis 31
Essential Role of DNAX Adaptor Protein 12 (DAP12) and Spleen Tyrosine Kinase (Syk) in Inflammation-Driven Immune Dysfunction in Rodent Model of Colitis 30
‘The Farnesoid X Receptor Promotes Adipocyte Differentiationd regulates adipose cell function in vivo’ 29
Molecular Determinants of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in a Model of Peritoneal Gastric Cancer Carcinogenesis 29
H2S Induces Analgesia Is Mediated In Vivo Activation of mu Opioid Receptor and PI3K/AKT Pathway Activation 28
The bile acid sensor FXR regulates insulin transcription and secretion. 28
Impaired calcineurin signaling in myeloid cells results in downregulation of pentraxin-3 and increased susceptibility to aspergillosis 28
A Novel Source of Intestinal Damage: The HIV Protease Inhibitor Ritonavir Worsens Damage Caused by COX Inhibitors 28
The CCR5 Antagonist Maraviroc Reduces the Potential for Gastric Cancer Dissemination in Rodent Models of Peritoneal Metastasis 28
Heat shock proteins as key biological targets of the marine natural cyclopeptide perthamide 27
The Bile Acid Receptor TGR5 Maintains Gastrointestinal Homeostasis and Its Activation Rescues From Gastrointestinal Injury Caused by ASA and NSAIDs 27
Enhanced anti-inflammatory activity of hydrogen sulfide releasing derivative of mesalamine in rodent models of colitis, involves direct inhibition of Nf-kappa B 27
Role of Maraviroc in a dyslipidemic murine model of atherosclerosis RTV-induced 27
Solomonsterol A, a marine pregnane-X-receptor agonist, attenuates inflammation and immune dysfunction in a mouse model of arthritis. 25
VSL#3 Resets Insulin Signaling and Protects against NASH and Atherosclerosis in a Model of Genetic Dyslipidemia and Intestinal Inflammation. 24
The Farnesoid X Receptor Promotes Adipocyte Differentiation and Regulates Adipose Cell Function in Vivo 23
Celecoxib exacerbates gastrointestinal damage induced by aspirin but not by NO-aspirin (NCX-4016): A randomised, parallel group, blind-observer endoscopic study. Evidence for a protective role of NO in the gastrointestinal mucosa 23
Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome. 23
The bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammation 23
The Nuclear Receptor SHP Mediates Inhibition of Hepatic Stellate Cells by FXR and Protects Against Liver Fibrosis 22
Plakilactones from the Marine Sponge Plakinastrella mamillaris. Discovery of a New Class of Marine Ligands of Peroxisome Proliferator-Activated Receptor gamma 22
Modification of Intestinal Microbiota by VSL#3 Protects Against Development of Pain in the Neonatal Maternal Separation Model. a Whole Genome Array Investigation 22
Inhibition of NF-kB by a PXR-Dependent Pathway Mediates Counter-regulatory Activities of Rifaximin on Innate Immunity in Intestinal Epithelial Cells 22
FXR Activation Corrects Immune-Dysfunction and Attenuates Inflammation in a Rodent Model of Hepatitis 21
Gastrointestinal safety and anti-inflammatory activity of HCT-1026, NO-releasing flurbiprofen, in healthy humans volunteers 21
Totale 4.446
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.645
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.645
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201952 0 0 0 0 0 0 0 0 0 0 52 0
2019/2020395 23 20 51 4 57 21 60 12 86 38 6 17
2020/2021884 3 78 41 91 253 37 50 8 74 20 70 159
2021/2022877 15 152 9 32 32 120 5 274 4 8 75 151
2022/20231.563 116 295 8 154 114 173 1 84 556 0 50 12
2023/2024372 35 67 36 4 4 4 109 36 32 17 28 0
Totale 4.446